Immunome Inc.

Pharmaceutical Preparations

IMNM Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001472012 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$2.80B
113,577,629 shares Covers every share class this company has on file.
Insiders on file
7
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$143.64M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
5.13%
insider-held value divided by market capitalisation

What Immunome Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$6.94M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$212.39M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
247
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Immunome Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against Immunome Inc..
Insider Reported role Shares Value Last action
Officers 3
Max Rosett Max Rosett CFO 47,476 $1.27M A Grant or award Jul 23, 2026 position reported
Philip Tsai CTO 43,300 $1.16M A Grant or award Jul 23, 2026 position reported
Jack Higgins Other Executive 40,729 $1.09M A Grant or award Jul 23, 2026 position reported
Officers who also sit on the board 1
Clay B. Siegall CEO 690,704 $18.48M A Grant or award Jul 23, 2026 position reported
Directors 3
Isaac Barchas Board Member 4,165,824 $111.48M S Open-market sale Aug 12, 2026 position reported
Philip Wagenheim Board Member 341,147 $9.13M S Open-market sale Mar 23, 2026 position reported
Jean Jacques Bienaime Board Member 38,415 $1.03M P Open-market purchase Jun 5, 2026 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

3 insiders bought Immunome Inc. (IMNM) shares worth $1,221,179 between Mar 24, 2025 and Mar 26, 2025

Cluster buying

3 different insiders made 4 open-market purchases of this company’s shares within a short window. Each row below is one reported trade.

3 insiders bought Immunome Inc. (IMNM) shares worth $1,221,179 between Mar 24, 2025 and Mar 26, 2025
Date Insider Transaction Shares Price Value Filing
Mar 24, 2025 Jean Jacques Bienaime P Open-market purchase 7,000 held after: 23,615 $8.21 $57,470 SEC filing ↗
Mar 24, 2025 Philip Tsai P Open-market purchase 12,300 held after: 33,300 $8.42 $103,566 SEC filing ↗
Mar 25, 2025 Jean Jacques Bienaime P Open-market purchase 7,800 held after: 31,415 $7.78 $60,684 SEC filing ↗
Mar 26, 2025 Clay B. Siegall P Open-market purchase 137,100 held after: 806,736 $7.29 $999,459 SEC filing ↗

Total of the rows above: $1,221,179, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 64 rows we hold, 24 are open-market purchases (P) and 22 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Immunome Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Aug 12, 2026 Isaac Barchas S Open-market sale 11,048 $27.25 $301.1K SEC filing ↗
Aug 11, 2026 Isaac Barchas S Open-market sale 62,291 $26.23 $1.63M SEC filing ↗
Aug 10, 2026 Isaac Barchas S Open-market sale 10,125 $26.07 $264.0K SEC filing ↗
Aug 7, 2026 Isaac Barchas S Open-market sale 15,248 $26.06 $397.4K SEC filing ↗
Aug 6, 2026 Isaac Barchas S Open-market sale 20,840 $26.06 $543.1K SEC filing ↗
Jul 23, 2026 Philip Tsai A Grant or award 38,250 $0.00 $0 SEC filing ↗
Jul 23, 2026 Max Rosett A Grant or award 47,250 $0.00 $0 SEC filing ↗
Jul 23, 2026 Jack Higgins A Grant or award 38,250 $0.00 $0 SEC filing ↗
Jul 23, 2026 Clay B. Siegall A Grant or award 180,000 $0.00 $0 SEC filing ↗
Jul 7, 2026 Isaac Barchas S Open-market sale 16,906 $24.20 $409.1K SEC filing ↗
Jul 6, 2026 Isaac Barchas S Open-market sale 83,094 $24.11 $2.00M SEC filing ↗
Jul 2, 2026 Isaac Barchas S Open-market sale 24,335 $23.33 $567.7K SEC filing ↗
Jul 2, 2026 Isaac Barchas S Open-market sale 75,665 $22.35 $1.69M SEC filing ↗
Jun 30, 2026 Isaac Barchas S Open-market sale 101,050 $21.12 $2.13M SEC filing ↗
Jun 15, 2026 Max Rosett S Open-market sale 60,000 $18.23 $1.09M SEC filing ↗
Jun 15, 2026 Max Rosett M Option exercise or conversion 60,000 $1.05 $63.0K SEC filing ↗
Jun 5, 2026 Jean Jacques Bienaime P Open-market purchase 1,000 $19.27 $19.3K SEC filing ↗
Jun 5, 2026 Jean Jacques Bienaime P Open-market purchase 3,500 $19.46 $68.1K SEC filing ↗
Jun 5, 2026 Jean Jacques Bienaime P Open-market purchase 6,000 $19.48 $116.9K SEC filing ↗
Jun 5, 2026 Jean Jacques Bienaime S Open-market sale 10,000 $19.41 $194.1K SEC filing ↗
Jun 5, 2026 Jean Jacques Bienaime S Open-market sale 500 $19.44 $9.7K SEC filing ↗
May 15, 2026 Jean Jacques Bienaime P Open-market purchase 5,000 $20.70 $103.5K SEC filing ↗
Apr 2, 2026 Max Rosett S Open-market sale 1,344 $22.48 $30.2K SEC filing ↗
Apr 2, 2026 Max Rosett S Open-market sale 63,656 $21.91 $1.39M SEC filing ↗
Apr 2, 2026 Max Rosett M Option exercise or conversion 39,713 $1.35 $53.6K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Immunome Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Immunome Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.